Version 1
: Received: 11 April 2024 / Approved: 14 April 2024 / Online: 15 April 2024 (11:36:42 CEST)
How to cite:
Nakagaito, M.; Imamura, T.; Ushijima, R.; Nakamura, M.; Kinugawa, K. Impact of Withdrawal of SGLT2 Inhibitors on Clinical Outcomes in Patients with Heart Failure. Preprints2024, 2024040901. https://doi.org/10.20944/preprints202404.0901.v1
Nakagaito, M.; Imamura, T.; Ushijima, R.; Nakamura, M.; Kinugawa, K. Impact of Withdrawal of SGLT2 Inhibitors on Clinical Outcomes in Patients with Heart Failure. Preprints 2024, 2024040901. https://doi.org/10.20944/preprints202404.0901.v1
Nakagaito, M.; Imamura, T.; Ushijima, R.; Nakamura, M.; Kinugawa, K. Impact of Withdrawal of SGLT2 Inhibitors on Clinical Outcomes in Patients with Heart Failure. Preprints2024, 2024040901. https://doi.org/10.20944/preprints202404.0901.v1
APA Style
Nakagaito, M., Imamura, T., Ushijima, R., Nakamura, M., & Kinugawa, K. (2024). Impact of Withdrawal of SGLT2 Inhibitors on Clinical Outcomes in Patients with Heart Failure. Preprints. https://doi.org/10.20944/preprints202404.0901.v1
Chicago/Turabian Style
Nakagaito, M., Makiko Nakamura and Koichiro Kinugawa. 2024 "Impact of Withdrawal of SGLT2 Inhibitors on Clinical Outcomes in Patients with Heart Failure" Preprints. https://doi.org/10.20944/preprints202404.0901.v1
Abstract
Background: The clinical impact of withdrawal of sodium-glucose cotransporter 2 inhibitor (SGLT2i) on the all-cause readmission in patients with heart failure remains unknown. Methods: Consecutive 212 patients who were hospitalized for heart failure and received SGLT2i during the index hospitalization between February 2016 and July 2022 were evaluated. Of these, 51 patients terminated SGLT2i during or after their index hospitalization. The primary outcome was defined as an all-cause readmission rates/times. Results: Over a median of 23.2 months, an all-cause readmission occurred in 38 of 51 patients (74.5%) withdrawn from SGLT2i and 93 of 161 patients (57.8%) with continuation of SGLT2i (p = 0.099). The total number of all-cause readmissions per year was 0.97 [0-1.50] in patients withdrawn from SGLT2i and 0.50 [0-1.03] in patients with continuation of SGLT2i (p = 0.030). There was no significant difference in total medical cost (62,906 [502-187,246] versus 29,236 [7,920-180,305] JPY per month, p = 0.866) between both patient groups. Conclusions: Termination of SGLT2i may be associated with incremental all-cause readmission and no benefit in reducing total medical costs.
Keywords
heart failure; SGLT2 inhibitor; hospitalization; medical cost
Subject
Medicine and Pharmacology, Cardiac and Cardiovascular Systems
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
